Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reflect high enthusiasm for orforglipron, illustrated by phrases such as 'very exciting time' and 'dramatic pace of innovation,' highlighting its potential to expand obesity treatment options. The tone and choice of words, like 'promising results' and 'similar side effects,' contribute to a perception of meaningful progress, though some mention side effects like nausea, which tempers the overall optimism.
Most discussions recognize the promising results of orforglipron, with some highlighting its comparable efficacy to existing treatments, indicating moderate agreement on its significance.
The discussions consistently show high interest, emphasizing the novelty of an oral GLP-1 receptor agonist and its potential impact on obesity management.
While many posts discuss the trial results and side effects, the depth varies, with some providing detailed insights and others merely noting the findings.
The shared information suggests a substantial potential to influence treatment options for obesity, considering the mention of growing therapeutic benefits and the recent publication in a prominent journal.
Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with -9.4% to -14.7% weight loss. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. https://t.co/vyuRxEICej https://t.co/W76gyKF1zJ
@SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/om9ymEVO7z
Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. https://t.co/vyuRxEJa3R https://t.co/itipwMohSH
دوستان تا مدتی بعد امکان داره قرص خوراکی با اثر مشابه اوزمپیک بیاد به بازار. قیمت میاد پایین و بنظرم بشدت نتایجش در سطح جامعه جذاب خواهد بود. در موردش بخونید وقت داشتین. https://t.co/E4BSlxvMwa
Also, while I think Viking won't launch with the empty stomach/fasting requirement, AFAIK, it's unconfirmed. Weird, no? I am also curious about titration between orals and injectables. Sources: https://t.co/b4Rhcbffjs https://t.co/PxoOaDpIWZ https://t.co/0bK87iY7ft
$LLY analyst take $LLY's Phase 2 orforglipron data shows similar change weight loss at week 4, caveat: shows more mild/moderate nausea/GI events compared to Phase 1 VK2735. $VKTX Tolarabity Tolarabity Tolarabity https://t.co/dSJw2MDS0P
Ref: httpswwwnejmorgdoi101056NEJMoa2302392 and httpswwwnejmorgdoi101056NEJMoa2301972. Orforglipron, an oral GLP-1 receptor agonist, shows significant weight loss efficacy in adults with obesity, with 8.6% to 14.7%…
Orforglipron is a nonpeptide GLP-1 receptor agonist developed for weight management and diabetes treatment. In a phase 2 trial, participants experienced significant weight loss with manageable side effects…
@JCanNuSH @NEJM Thank you Should have said glp1 agonist https://t.co/fbdUUlMRQr
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/l5xozzPBuh via @NEJM
@dikoros2 @Pierrakakis Που να δεις και σε λίγο που θα ειναι σε χαπάκια κι όχι ενέσιμα https://t.co/8XdakvObOR
Also, while I think Viking won't launch with the empty stomach/fasting requirement, AFAIK, it's unconfirmed. Weird, no? I am also curious about titration between orals and injectables. Sources: https://t.co/b4Rhcbffjs https://t.co/PxoOaDpIWZ https://t.co/0bK87iY7ft
RT @TonyFauci2: $LLY new oral Obesity Candidate has much worse safety profile than does $VKTX Oral VK2735 - $LLY - nausea, 37 to 58% with…
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | New England Journal of Medicine https://t.co/3epGleCst6
RT @skathire: New GLP1 Agonist orfoglipron - once daily - oral - non-peptide - no food or water restriction 2 Phase 2 trials Weight: up…
RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…
RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…
RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…
RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…
RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…
RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…
RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…
RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…
RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…
RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…
@SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/om9ymEVO7z
@thisisamammad https://t.co/JUFh3NPLa3
@mooooonlighgir https://t.co/JUFh3NPLa3
RT @thewhy6uy: دوستان تا مدتی بعد امکان داره قرص خوراکی با اثر مشابه اوزمپیک بیاد به بازار. قیمت میاد پایین و بنظرم بشدت نتایجش در سطح جامع…
دوستان تا مدتی بعد امکان داره قرص خوراکی با اثر مشابه اوزمپیک بیاد به بازار. قیمت میاد پایین و بنظرم بشدت نتایجش در سطح جامعه جذاب خواهد بود. در موردش بخونید وقت داشتین. https://t.co/E4BSlxvMwa
danuglipron was discontinued but orforglipron awaits approval. #GLP-1Agonists #weightloss #type2diabetes Phase 2 study: DOI: 10.1056/NEJMoa2302392 Phase 3 trials: https://t.co/RVsesOcRMu https://t.co/SPZEaXhCfl
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | New England Journal of Medicine https://t.co/HFYHKQJtJR
■ファイザー、 経口GLP-1「ダヌグリプロン」開発中止 ファイザーが開発中の低分子経口GLP-1「ダヌグリプロン」の開発中止を発表。 これで食事制限なし経口GLP-1の開発は、リリーの「オルフォグリプロン」のみになります。 https://t.co/Yok98iBzB1
RT @TonyFauci2: $LLY Safety Fail: “nausea ranged from 37% to 58% across the orforglipron dose cohorts and was 10% in the placebo group. The…
$LLY Safety Fail: “nausea ranged from 37% to 58% across the orforglipron dose cohorts and was 10% in the placebo group. The incidence of vomiting ranged from 14% to 32% with orforglipron” $VKTX safest. https://t.co/AzB6YoSfdR
È stata dimostrata una riduzione del peso dell’8%. 5/ https://t.co/EMo0vCHeQT
RT @TonyFauci2: $LLY new oral Obesity Candidate has much worse safety profile than does $VKTX Oral VK2735 - $LLY - nausea, 37 to 58% with…
RT @TonyFauci2: $LLY new oral Obesity Candidate has much worse safety profile than does $VKTX Oral VK2735 - $LLY - nausea, 37 to 58% with…
RT @YAYshamsaldeen: @LillyPad @US_FDA @EliLillyandCo متوقع في شهر أغسطس٢٠٢٥، ظهور نتائج التجارب الإكلينيكية المرحلة3️⃣للدواء التجريبي
RT @YAYshamsaldeen: @LillyPad @US_FDA @EliLillyandCo متوقع في شهر أغسطس٢٠٢٥، ظهور نتائج التجارب الإكلينيكية المرحلة3️⃣للدواء التجريبي
@LillyPad @US_FDA @EliLillyandCo متوقع في شهر أغسطس٢٠٢٥، ظهور نتائج التجارب الإكلينيكية المرحلة3️⃣للدواء التجريبي
RT @TonyFauci2: $LLY new oral Obesity Candidate has much worse safety profile than does $VKTX Oral VK2735 - $LLY - nausea, 37 to 58% with…
$LLY new oral Obesity Candidate has much worse safety profile than does $VKTX Oral VK2735 - $LLY - nausea, 37 to 58% with orforglipron and 10% with placebo; for vomiting, 14 to 32% with orforglipron and 6% with placebo https://t.co/AzB6YoRHoj $VKTX - “Mild nausea was reported
@doctorValenti @fjavesc @Nature @JAMA_current @JAMASurgery @obesidadSECO @aec_obesidad @TheLancet @NEJM @ctueroo
@Jwaitz @ChristosArgyrop @thisis_drgsp @NephroSeeker @arvindcanchi How about this molecule? @LittleBigGloms Orforglipron from Eli Lilly https://t.co/NtQeoiMHpA (Yeah likely to be costly but syringe needle supply issues will be less) #NephJC https://t.co/OASvJzwVwW
@Factor_XII trial https://t.co/TUxqESHBsy
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | New England Journal of Medicine https://t.co/1iECynVtwD
RT @RajeevJayadevan: Orforglipron is an oral partial GLP-1 agonist found to reduce 10% weight within 6 months in about 3/4 people using it.…
RT @RajeevJayadevan: Orforglipron is an oral partial GLP-1 agonist found to reduce 10% weight within 6 months in about 3/4 people using it.…
RT @RajeevJayadevan: Orforglipron is an oral partial GLP-1 agonist found to reduce 10% weight within 6 months in about 3/4 people using it.…
RT @RajeevJayadevan: Orforglipron is an oral partial GLP-1 agonist found to reduce 10% weight within 6 months in about 3/4 people using it.…
RT @RajeevJayadevan: Orforglipron is an oral partial GLP-1 agonist found to reduce 10% weight within 6 months in about 3/4 people using it.…
Orforglipron is an oral partial GLP-1 agonist found to reduce 10% weight within 6 months in about 3/4 people using it. The drop out rate due to gastrointestinal side effects was 10-17% in this RCT. https://t.co/r45xizTApw https://t.co/t3tKPmhoN4 https://t.co/WAXzX452Rs
RT @semodough: $LLY analyst take $LLY's Phase 2 orforglipron data shows similar change weight loss at week 4, caveat: shows more mild/moder…
RT @semodough: $LLY analyst take $LLY's Phase 2 orforglipron data shows similar change weight loss at week 4, caveat: shows more mild/moder…
RT @semodough: $LLY analyst take $LLY's Phase 2 orforglipron data shows similar change weight loss at week 4, caveat: shows more mild/moder…
$LLY analyst take $LLY's Phase 2 orforglipron data shows similar change weight loss at week 4, caveat: shows more mild/moderate nausea/GI events compared to Phase 1 VK2735. $VKTX Tolarabity Tolarabity Tolarabity https://t.co/dSJw2MDS0P
RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…
RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…
RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…
RT @ZHeart11768530:
RT @ZHeart11768530:
RT @ZHeart11768530:
RT @ZHeart11768530:
RT @ZHeart11768530:
RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…
RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…
RT @ZHeart11768530:
RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…
RT @ZHeart11768530:
RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…
RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…
RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…
3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinology https://t.co/Raibrrc8et
RT @scottisaacsmd: Daily oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse…
RT @scottisaacsmd: Daily oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse…
RT @scottisaacsmd: Daily oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse…
RT @ringo_diabetes: 現在経口のGLP1RAはリベルサスのみですが内服時の注意事項が多く吸収が不安定な点がデメリットとして挙げられます。今後発売が期待されている新たな低分子GLP1RAとしてはPfizerのDanuglipron、Lilyのorforglipr…
現在経口のGLP1RAはリベルサスのみですが内服時の注意事項が多く吸収が不安定な点がデメリットとして挙げられます。今後発売が期待されている新たな低分子GLP1RAとしてはPfizerのDanuglipron、Lilyのorforglipronが2相まで通過しています。 https://t.co/AJngsesl0i https://t.co/ti08nUYkqg
As $VKTX runs another 5% today, if it seems the obesity/metabolic drug space is crowded, think again. $LLY is attempting to pre-solve for the supply constraint expected for the oral version of these meds. https://t.co/1IRzPWGyiS
RT @EricTopol: At #ADA2023 and @NEJM today @AmDiabetesAssn A GLP-1 pill randomized trial for weight loss https://t.co/JyPRGduP0g Not as mu…
Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight loss of almost 15% with similar side effects to injectable GLP-1 receptor agonists. https://t.co/vyuRxEICej https://t.co/k38EBAe9dQ
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…
Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with -9.4% to -14.7% weight loss. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. https://t.co/vyuRxEICej https://t.co/W76gyKF1zJ
RT @DrBobGabbay: A study on a new ORAL GLP-1 with 9.4% to 14.7% weight loss. The pace of innovation is dramatic providing more options to…
RT @rengerwitkamp: Farma juicht, voeding siddert en aandelen worden herbelegd. De nieuwe oraal toe te passen GLP-1 agonisten en krachtige T…
Wharton et al. reported that treatment with #orforglipron resulted in weight reduction and related benefits similar to efficacy outcomes observed with injectable GLP-1RAs, already approved for weight management. Learn more on the CMF today: https://t.co/2ENPRwPV7Z
Journal Club SID Trattamento dell’obesità: arrivano anche le formulazioni orali? - A cura di Danila Capoccia https://t.co/Y2FO8eiD9W
Wharton, et al. reported that treatment with #orforglipron resulted in weight reduction and related benefits similar to efficacy outcomes observed with injectable GLP-1RAs that have already been approved for weight management. Learn more on the CMF: https://t.co/J03jQs6sV6
The latest research by Wharton, et al. evaluated the efficacy and safety of orforglipron in adults with obesity, or who were overweight with at least one weight-related coexisting condition, and without T2D. Get all the key insights over on the #CMF today: https://t.co/2ENPRwPnir
Want to learn more about the daily oral GLP-1 receptor agonist #orforglipron for adults with obesity? Head on over to the #CMF today and get all the insights from the latest publication by Wharton, et al: https://t.co/2ENPRwPnir https://t.co/DYG1hVXgYS
We’ve just updated our detailed slide decks; this month includes the latest publication by Wharton, et al on #orforglipron for adults with #obesity. Head on over to the #CMF for free to access key publications in the world of cardiometabolic therapy: https://t.co/2ENPRwPV7Z https://t.co/IhHIv1L6Uc
Farma juicht, voeding siddert en aandelen worden herbelegd. De nieuwe oraal toe te passen GLP-1 agonisten en krachtige Triple–Hormone-Receptor agonisten komen eraan. Zullen we ze maar gewoon toevoegen aan het drinkwater of toch gaan nadenken ? NEJM https://t.co/F2Bk3xcIQm
RT @vic_pallares: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM
RT @DrBobGabbay: A study on a new ORAL GLP-1 with 9.4% to 14.7% weight loss. The pace of innovation is dramatic providing more options to…
【#NEJM日本国内版オンライン】 ★2023年9月に最も読まれた記事は⇒ 第1位 肥満成人に対する GLP-1 受容体作動薬オルフォルグリプロンの連日経口投与 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity S. Wharton and Others 日本語アブストラクト https://t.co/uF5OLRQV0D
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/boAOeoFyZQ
RT @DrBobGabbay: A study on a new ORAL GLP-1 with 9.4% to 14.7% weight loss. The pace of innovation is dramatic providing more options to…
RT @DrBobGabbay: A study on a new ORAL GLP-1 with 9.4% to 14.7% weight loss. The pace of innovation is dramatic providing more options to…
A study on a new ORAL GLP-1 with 9.4% to 14.7% weight loss. The pace of innovation is dramatic providing more options to treat obesity. @AmDiabetesAssn @ADA_DiabetesPro #obesity #GLP1 https://t.co/kRS9XRGUiw
RT @eemh_hasl: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/u28mUshAO3
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/u28mUshAO3
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/AWtILpfOcw
Estudio comentado por el Dr. Ignacio Llorente Gómez de Segura
RT @ObesitySeen:
RT @ObesitySeen:
RT @XBayona:
RT @ObesitySeen:
RT @Xiaoliu000928: Small molecule oral GLP-1 aolgonist. Lilly's realm where their rivals have lost their power? Daily Oral GLP-1 Receptor A…
Small molecule oral GLP-1 aolgonist. Lilly's realm where their rivals have lost their power? Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/HfO2TJr9bO
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/WQsZT39qan
RT @2minmed: #VisualAbstract: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity #StudyGraphics #obesity https://t.co/…
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2302392?query=featured_home
#VisualAbstract: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity #StudyGraphics #obesity https://t.co/WzSBa63d3F https://t.co/e16hxZQs1D
RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/oCiD1VdPAi
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/5b7uFrPuex
Se van consolidando las evidencias q recomiendan el control farmacológico de la obesidad Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/2bjeyFUDNJ
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/mpV4UsLqEg
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJMالتوصيات العلمية الجديده تقر استخدام الادوية لتخفيف الوزن https://t.co/wZuGIZ5ISr
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/rv5Y0e6T9V
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/4mSvLcc9J2
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @florencarral: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/ehY8GkyYlv
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @vic_pallares: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…
Six months of @EliLillyandCo once daily oral orforglipron allowed to achieve up to 13% weight reduction in adult #obesity patients https://t.co/rWjbyjpga3 #VisualAbstract #endocrinology https://t.co/tx50P6awSs
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…
Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. https://t.co/vyuRxEJa3R https://t.co/itipwMohSH
Weight loss effects with oral orforglipron - funny name, legit results. #GLP1 #weightloss #science @NEJM https://t.co/DEfBoqkUvq
すみません、オルフォグリフロン(空腹制限なし経口GLP-1) 肥満症への第2相試験のリンク【NEJM】が抜けていました 272名、平均BMI38、36週後オルフォ群最大量で-15%減量。オルフォ群で10-17%に投与中止につながる有害事象あり。 https://t.co/AwxdPWN6OR https://t.co/R1yuQq4h0F
RT @RevistaMFSamfyc: El agonista oral diario de GLP-1 orforglipron para adultos con obesidad https://t.co/gVpxtUjUTF PMID 37351564
RT @RevistaMFSamfyc: El agonista oral diario de GLP-1 orforglipron para adultos con obesidad https://t.co/gVpxtUjUTF PMID 37351564
El agonista oral diario de GLP-1 orforglipron para adultos con obesidad https://t.co/gVpxtUjUTF PMID 37351564
RT @DrJavierCrespo: Un nuevo actor en el tratamiento de la obesidad (y, quizás en un futuro inmediato en el tratamiento del #SLD). Excelent…
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/K97eC3ZPBW
RT @DrJavierCrespo: Un nuevo actor en el tratamiento de la obesidad (y, quizás en un futuro inmediato en el tratamiento del #SLD). Excelent…
RT @DrJavierCrespo: Un nuevo actor en el tratamiento de la obesidad (y, quizás en un futuro inmediato en el tratamiento del #SLD). Excelent…
RT @DrJavierCrespo: Un nuevo actor en el tratamiento de la obesidad (y, quizás en un futuro inmediato en el tratamiento del #SLD). Excelent…
Un nuevo actor en el tratamiento de la obesidad (y, quizás en un futuro inmediato en el tratamiento del #SLD). Excelentes resultados (no tan espectaculares como con Retatrutide), que nos acercan a un tratamiento a la carta de la obesidad. @sepdigestiva https://t.co/lJEuSYaBBT
■ADAのまとめメモ オルフォグリフロン(空腹制限なし経口GLP-1) 第2相試験 for 肥満,【NEJM】のリンクが抜けていました。スミマセン。 平均BMI38の272名、36週後の体重変化はオルフォ群で-9.4～-14.7％。オルフォ群の10-17%に投与中止につながる消化管症状。 https://t.co/AwxdPWN6OR https://t.co/P1wy8V5org
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/LI7Rhs4guG
GLP-1作動薬オルフォルグリプロンの経口投与ダイエットのRCT論文（NEJM） ✅有意な体重減少あり ✅有害事象は、注射のGLP-1 受容体アゴニストの報告と同程度 https://t.co/ThXxYKrSy4
【RCT】糖尿病でない肥満または体重関連の共存条件を1つ以上もつ過体重成人へのOrforglipronの投与は、プラセボの投与と比較して、体重を減少させた。 #ペ読 https://t.co/0A37r3PLkA
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/IAto8bZSRi イーライリリーすごいわ ニーズとマーケティング戦略に唸る
Full text links @NEJM Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/1E9FUwJy5T
Acceso en @PubMedOnline https://t.co/x1ONaKypO7
'Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists.' https://www.nejm.org/doi/full/10.1056/NEJMoa2302392?query=featured_home
The paper on 'Orforglipron' in "NEJM" the above "Nature" article is partly based upon, & links to: “Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity” 2/3 https://t.co/l4LqwHJaK8
RT @ConscienHealth: Early data on new incretins leads us to think therapeutic options for #obesity will be growing with real benefits accru…
RT @ConscienHealth: Early data on new incretins leads us to think therapeutic options for #obesity will be growing with real benefits accru…
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/RYrrUl8oWs
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/b09Ae5tSkS
RT @ConscienHealth: Early data on new incretins leads us to think therapeutic options for #obesity will be growing with real benefits accru…
Early data on new incretins leads us to think therapeutic options for #obesity will be growing with real benefits accruing to people living with the disease. Free access to the @NEJM publication on #orfoglipron available here. #ADA2023 #ADARME https://t.co/JWH0YFLDVh https://t.co/XzmOmsdLMi
10.1056/NEJMoa2302392. Epub 2023 Jun 23. PMID: 37351564. [6]http://www.newsthevoice.com/news/articleView.html?idxno=32782 [7]CagriSema and the link between ...
obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2302392 (2023). Lancet ...
(https://www.nejm.org/doi/full/10.1056/NEJMoa2302392). Plenty of weight-loss drugs have failed, too. Anti-obesity drugs with other targets – such as those ...
doi:10.1056/NEJMoa2302392 30. doi:10.1016/S0140-6736(23)01163-7 166 Saxena AR, Frias JP, Gorman DN, et al. Tolerability, safety and 176 Heymsfield SB ...
N Engl J Med 2023;389:877–88. of randomized controlled trials. Obes Surg 2019;29:964–74. https://doi.org/10.1007/ https://doi.org/10.1056/NEJMoa2302392
doi.org/10.1056/NEJMoa2302392. Writing - review & editing. Alexandra Klisic: Writing -original draft, [14] Cochrane Handbook for Systematic Reviews of ...
10.1056/NEJMoa2302392. 44. Ji, L., Jiang, H., Cheng, Z., et al. (2023). A phase 2 randomised controlled trial of mazdutide in chinese overweight adults or ...
出現中巨大 #減量薬市場 のリーダーはLillyに。 ttps://www.nejm. org/doi/full/10.1056/NEJMoa2302392.
DOI: 10.1056/NEJMoa2302392. You might also like. 41. PDF. No ratings yet. 41. 8 pages. Lilly's Oral GLP-1, Orforglipron, Delivers Weight Loss of Up To An ...
Erste Ergebnisse, dass GLP-1 eine diabetische Stoffwechsellage erheblich positiv beeinflussen kann, gab es bereits seit Dekaden.
N Engl J Med. 23 June 2023; DOI: 10.1056/NEJMoa2302392. 11. Brandt SJ, Müller TD, DiMarchi RD, et al.: Peptide-based multi-agonists: a new para- digm in ...
DOI: Page 8. 3. Perspektiven der Diabetologie 2/2023 | Deutsches Ärzteblatt. 10.1056/NEJMoa2302392. Epub 23. Juni 2023. PMID: 37351564. 60. Davies MJ, Aroda VR ...
org/doi/full/10.1056/nejmoa1411892 - https://www.nejm. org/doi/full/10.1056/NEJMoa2301972 - https://www.nejm. org/doi/full/10.1056/NEJMoa2302392. CODE and 28 ...
org/doi/full/10.1056/NEJMoa2302392 · May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE · May be a doodle of text that says 'ORFORELIFRON ...
DOI: 10.1056/NEJMoa2301972. (4) Sean Wharton et al.: Daily Oral GLP-1 Receptor Agonist Orfoglipron for ... DOI: 10.056/NEJMoa2302392. Posted on 2. Juli 2023 ...
... )00213-0/abstract https://www.nejm.org/doi/full/10.1056/NEJMoa2302392. more. View all 4 comments. 17 hours ago · aaepl_lille. •. Follow.
org/doi/full/10.1056/NEJMoa2302392. May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE. May be a doodle of text that says ...
org/doi/full/10.1056/NEJMoa2302392. May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE. May be a doodle of text that says ...
... /journals/lancet/article/PIIS0140-6736(21)00213-0/abstract https://www.nejm.org/doi/full/10.1056/NEJMoa2302392".
... )00213-0/abstract https://www.nejm.org/doi/full/10.1056/NEJMoa2302392. more. View all 4 comments. December 4. amande_naturopathe. •. Follow.
DOI: 10.1056/NEJMoa2302392; Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile ...
DOI:10.1056/NEJMoa2302392, https://www.nejm.org/doi/full/10.1056/NEJMoa2302392; Moiz, A., Filion, K. B., Tsoukas, M. A., et al. (2025). The ...
DOI:10.1056/NEJMoa2302392, https://www.nejm.org/doi/10.1056/NEJMoa2302392. Further Reading. All Glucagon-like Peptide-1 Content · How Oral GLP-1 ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2302392. more. View all 4 comments. December 4 · dr_jennettewatts's profile picture.
https://www.nejm.org/doi/full/10.1056/NEJMoa2302392. A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants ...
org/doi/full/10.1056/NEJMoa2302392. May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE. May be a doodle of text that says ...
DOI: 10.1056/NEJMoa2302392. RT: Dr. Leonardo Matthew - CRM-BA 31460 | CRM-SP 240346 (Este conteúdo tem caráter meramente educativo e não ...
... www.nejm.org/doi/full/10.1056/NEJMoa2302392. more. View all 4 comments. 2 days ago · whatsupdoc_mag's profile picture. whatsupdoc_mag. •. Follow.
org/doi/full/10.1056/NEJMoa2302392. May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE. May be a doodle of text that says ...
DOI: 10.1056/NEJMoa2302392. RT: Dr. Leonardo Matthew - CRM-BA 31460 | CRM-SP 240346 (Este conteúdo tem caráter meramente educativo e não ...
... 10.1056/NEJMoa2511774#:~:text=Conclusions,other%20GLP%2D1 ... https://www.nejm.org/doi/full/10.1056/NEJMoa2302392. more. View all 4 ...
... 10.1056/NEJMoa2302392. more. View all 4 comments. December 4 · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy.
For comparison, in the Phase 2 trials (https://www.nejm.org/doi/full/10.1056/NEJMoa2302392), 36mg led to 13.5% loss after just 36 weeks, and ...
The New England Journal of Medicine. 389 (10): 877–888. doi:10.1056/NEJMoa2302392. PMID 37351564. ^ Jump up to: ...
The New England Journal of Medicine. 389 (10): 877–888. doi:10.1056/NEJMoa2302392. PMID 37351564. ^ Jump up to: ...
org/doi/full/10.1056/NEJMoa2302392. May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE. May be a doodle of text that says ...
... 10.1056/NEJMoa2302392 VOL. 389 NO. 10 (I edited the original graphic from Molecular Metabolism 2021 to add Mounjaro and orforglipron and put ...
org/doi/full/10.1056/NEJMoa2302392)라는 2상 임상시험 결과를 발표했는데, 이는 세마글루타이드의 결과와 거의 비슷한 수준이다. (2) 화이자의 후보 ...
... 10.1056/NEJMoa2302392. Online ahead of print. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Log in ·
https://www.nejm.org/doi/full/10.1056/NEJMoa2302392 https://www.scientificamerican.com/article/beyond-ozempic-new-obesity-drugs-could-be ...
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/abstract https://www.nejm.org/doi/full/10.1056/NEJMoa2302392. 更多.
one_byte_stand. OP • 8mo ago. It's the one you deep throat. https://www.nejm.org/doi/full/10.1056/NEJMoa2302392. Upvote 2. Downvote Reply Award
... 10.1056/NEJMoa2302392. And early studies have shown people taking orforglipron for 36 weeks lost an average of 14.7% of their body weight ...
org/doi/full/10.1056/NEJMoa2302392. May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE. May be a doodle of text that says ...
org/doi/10.1056/NEJMoa2302392. 2. 中国新闻周刊：减肥又增肌，新的“神药”要来了？ 3. 华创新药：低剂量更好16周-5.8%，诺和诺德发布CB1反向激动剂 ...
... 10.1056/NEJMoa2302392. All of the reports on Viking is coming from the company created hype. They haven't published any research data in a ...
doi:10.1056/ NN8022-1922 Study Group. Efficacy of liraglutide ... and design of the SURMOUNT clinical development NEJMoa2302392 STEP 1 Study Group ...
doi:10.1056/NEJMoa2302392; Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 ...
... commented on “oral glp1s” in general. fireanpeaches. • 2y ago · https://www.nejm.org/doi/full/10.1056/NEJMoa2302392 · MTsumi. • 2y ago.
... 10.1056/NEJMoa2312382) The information presented here is not ... 10.1056/NEJMoa2302392) Lincoff et al 2023 NEJM, Semaglutide and ...
... 10.1056/NEJMoa2302392 Haven't heard about oral tirzep yet but I assume it's also in the works. Exciting_Ad5538. • 2y ago.
2023;doi:10.1056/NEJMoa2302392. Younossi Z, et al. Hepatology. 2019;doi:10.1002/hep.30251. Sobia Nasir Laique, MD. Gastroenterology and ...
doi:10.1056/NEJMoa2302392. [3] Wilding, John P H et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” The New England ...
148. 148. 153. This article waspublished on June 23, 2023, at NEJM.org. DOI: 10.1056/NEJMoa2302392. 156. DE LA DIABESIDAD ALA METABESIDAD ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2302392; Drummond, S.P.; Bartnik, E.; Kouvatsos, N.; et al. The Recombinant Link Module of Human ...
2023;doi:10.1056/NEJMoa2302392. Wharton S, et al. Postgrad Med. 2022;doi:10.1080/00325481.2021.2002616. For more information: Zachary Abe ...
doi:10.1056/NEJMoa2302392. Newsletter. Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy ...
org/doi/full/10.1056/NEJMoa2302392. Gabriella Paolicelli and 823 others ·
DOI: 10.1056/NEJMoa2302392. ②The New England Journal of Medicine：Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia.
doi: 10.1056/NEJMoa2302392; https://www.nejm.org/doi/10.1056/NEJMoa2302392 · PubMed. Wharton S , ; GZGI Investigators . Daily oral GLP-1 ...
Wharton S, et al. N Engl J Med. 2023;doi:10.1056/NEJMoa2302392. For more information: Jamy D. Ard, MD, can be ...
Agonisten des auch natürlicherweise im Darm gebildeten Peptidhormons GLP-1 (Glucagon-like Peptide-1) sind nicht neu. Semaglutid und andere ...
... 10.1056/NEJMoa2302392. Epub ahead of print. PMID: 37351564. Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Mather KJ, Haupt A ...
... 10.1056/NEJMoa2302392) zeigen. nec. Zum Weiterlesen anmelden. Liebe Leserinnen und Leser,. dieser Beitrag ist nur für eingeloggte Benutzer ...
org/doi/full/10.1056/NEJMoa2302392?query=TOC&cid=NEJM%20eToc,%20June%2029,%202023%20DM2249964_NEJM_Subscriber&bid=1647391664. 本文技术观点不 ...
doi:10.1056/NEJMoa2302392; Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a ...
org/doi/full/10.1056/NEJMoa2302392. 2. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972. 3. https://www.nature.com/articles/d41586-023 ...
DOI: 10.1056/NEJMoa2302392. Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2302392. 期刊信息. The New England Journal of Medicine：《新 ...
... 10.1056/NEJMoa2302392 #ADA2023. Log in ·
... 23, 2023 DOI: 10.1056/NEJMoa2302392 ✓June 23, 2023 DOI:.org/10.1016/S0140-6736(23)01302-8 LANCET https://lnkd.in/e5ggtaYV.
org/doi/full/10.1056/NEJMoa2302392. 各位读者. 科研小助手官方QQ群：. 发布于：山西省. 平台声明. 评论. 全部. 还没有人评论过，快来抢首评. 写评论.
DOI: 10.1056/NEJMoa2302392. ②The New England Journal of Medicine：A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. 临床试验 ...
... 10.1056/NEJMoa2302392. Secondary Source. The Lancet. Source Reference: Frias JP, et al "Efficacy and safety of oral orforglipron in patients ...
Reference: Wharton S, et al. N Engl J Med. 2023:doi:10.1056/NEJMoa2302392. Perspective. Back to ...
2023;10.1056/NEJMoa2302392. doi:10.1056/NEJMoa2302392; Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2302392.
https://www.nejm.org/doi/full/10.1056/NEJMoa2302392.
New oral form of GLP-1 receptor agonist with 14% weight loss at 36 weeks! #AOM #obesitymedicine #bariatricsurgery.
https://www.nejm.org/doi/full/10.1056/NEJMoa2302392.
https://www.nejm.org/doi/full/10.1056/NEJMoa2302392.
https://www.nejm.org/doi/full/10.1056/NEJMoa2302392.
https://www.nejm.org/doi/full/10.1056/NEJMoa2302392.
https://www.nejm.org/doi/full/10.1056/NEJMoa2302392.
... 10.1056/NEJMoa2302392?query=featured_home. Log in ·
... 10.1056/NEJMoa2302392?query=featured_home | Facebook. Log in ... org/doi/full/10.1056/NEJMoa2302392?query=feature d_home. Sonja Imnoy ...
... with Obesity. DOI: 10.1056/NEJMoa2302392 #orforglipron #Ozempic #Wegovy #semaglutide #Mounjaro #減重#減肥#糖尿病. Log in ·
org/doi/full/10.1056/NEJMoa2302392. May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE. May be a doodle of text that says ...
org/doi/full/10.1056/NEJMoa2302392 · May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE · May be a doodle of text that says ...
org/doi/full/10.1056/NEJMoa2302392 · May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE · May be a doodle of text that says ...
org/doi/full/10.1056/NEJMoa2302392. 可能是包含下列内容的图片：上面的文字是“LA NEWS INDUS. 可能是包含下列内容的涂鸦：上面的文字是“ORFORELIFRON ...
org/doi/full/10.1056/NEJMoa2302392. May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE. May be a doodle of text that says ...
... のリーダーはLillyに。 ttps://www.nejm. org/doi/full/10.1056/NEJMoa2302392.
org/doi/full/10.1056/NEJMoa2302392 · May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE · May be a doodle of text that says ...
org/doi/full/10.1056/NEJMoa2302392 · May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE · May be a doodle of text that says ...
org/doi/full/10.1056/NEJMoa2302392 · May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE · May be a doodle of text that says ...
org/doi/full/10.1056/NEJMoa2302392 · May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE · May be a doodle of text that says ...
SI
دم
TW
C
D
AP
DM
NK
T
PN
TA
Z
با
عق
Ø
A
A
فا
F
A
اا
دح
OO
M
D糖
T
AM
O
H
اا
دا
G
CS
SS
AM
AD
C
M
DW
DM
DV
RJ
O
O
AA
DP
TK
J
S
P
M
SA
DL
NH
EE
HC
WE
TH
GJ
A
SK
N
S
UA
دس
MS
り
G
DA
MB
NS
KV
P
A
VH
NR
EJ
AN
HR
VS
CD
CS
IE
DS
AA
DL
BT
A
VT
TD
DV
JW
จอ
PA
RC
DA
BN
DG
DF
ES
S
A
EM
CÁ
BJ
H
FH
BD
AW
DA
FP
CP
DE
N
AP
TF
SI
AG
S
南公
BM
SM
D
DB
MS
H
TT
SS
DA
JA
XB
NV
O
C
오
PM
MM
DP
DD
MG
RG
C
L
ER
BB
JO
TL
SA
JF
LH
GW
HH
دا
MS
EG
MG
MP
GN
PF
JM
KE
NS
IK
AM
RF
DP
NX
D
JM
JN
EC
E
EP
PF
S
FZ
DR
A江
JA
EJ
DB
MD
IM
RM
MM
HS
FM
VC
み
KG
TC
HM
AM
S
H施
陈진
CD
NM
A
MJ
DT
HH
G
MM
DM
HE
RC
LF
RZ
DJ
FF
S
LF
AM
RM
SS
S
JC
EO
X
JC
GM
P食
P
猫
RD
AW
TK
T
RR
S